Multiple sclerosis (MS), an inflammatory disease of the central nervous system, is characterized by progressive neuronal loss and worsening physical disability. Although there are a number of currently marketed therapies that target the immune component of MS, including interferon-beta (IFN-beta) therapy and Teva Copaxone (glatiramer acetate), few available drugs are able to reduce or reverse disability progression. There is great opportunity for emerging agents that are neuroprotective, as well as for therapies that offer greater convenience and improved quality of life for MS patients.

Using tiering and restrictions data from Fingertip Formulary, as well as insight from 51 pharmacy directors, this report determines the key trends in reimbursement of MS treatments, drivers of these trends, and how stakeholders can capitalize on future shifts in coverage to steal share from the competition and provides insight for stakeholders looking to capitalize on future shifts in coverage in order to better position their products among competitors.


Related Reports

Formulary Advantages in Type 2 Diabetes:Rebates and discounts dictate the formulary position of branded therapies among some U.S. health plans.

According to the Centers for Disease Control and Prevention (CDC), an estimated 25.8 million people in the United States have diabetes. Diabetes is the leading cause of kidney failure, nontraumatic lo...

View Details

Formulary Advantages in Atrial Fibrillation: How Will MCO Size Affect the Design of Factor Xa Formularies?

In the coming years, atrial fibrillation (AF) patients will increasingly have more choice for anticoagulation therapy. Although Boehringer Ingelheim’s Pradaxa (dabigatran etexilate) and emerging facto...

View Details

Formulary Advantages in Asthma and COPD Therapies: Formulary Advantages in Asthma and COPD Therapies - Abstract

The market for asthma and chronic obstructive pulmonary disease (COPD) has grown notably in recent years because of increasing prevalence and diagnosis rates for both conditions as well as the greater...

View Details

Formulary Advantages in Psychiatric Drugs: Medicare plans readily employ cost-sharing measures and formulary restrictions to direct early use of generics and preferred brands for psychiatry.

According to the National Institute of Mental Health, each year tens of millions of Americans are affected by mental illness. Although significant strides have been made toward understanding the patho...

View Details